© 2021 MJH Life Sciences and Drug Topics. All rights reserved.
© 2021 MJH Life Sciences™ and Drug Topics. All rights reserved.
April 26, 2021
Tremfya phase 3 data shows skin clearance rates were maintained at 5 years with 55.5% of patients achieving an IGA score of 0% and 53% achieving PASI 100 response in VOYAGE 2 trial.
April 21, 2021
Research presented at Academy of Managed Care Pharmacy’s 2021 virtual conference evaluated tolerance and adherence to oral disease-modifying therapies for relapsing-remitting multiple sclerosis.
April 15, 2021
April 08, 2021
AbbVie submitted an application to the FDA for the use of risankizumab-rzaa, 150 mg (Skyrizi) in adults with active psoriatic arthritis.
March 19, 2021
Ponesimod was shown to be superior to teriflunomide in the rate of confirmed relapses and the number of new or enlarged T1 and T2 lesions.
March 09, 2021
Pharmacists can play an important role as part of the interdisciplinary care team.
March 02, 2021
Preliminary findings suggest patients with multiple sclerosis who are taking cladribine can mount and maintain effective vaccine responses.
February 11, 2021
Pharmacists can advise patients on how to control symptoms and reduce exacerbations.
February 01, 2021
The intramuscular administration of peginterferon beta-1a (Plegridy; Biogen) offers patients with relapsing multiple sclerosis a new treatment option.
January 26, 2021
Voclosporin (Lupkynis; Aurinia Pharmaceuticals) is indicated in combination with a background immunosuppressive therapy for the treatment of active lupus nephritis in adults.